Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents

No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel re...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2010-02, Vol.105 (3), p.293-296
Main Authors: Sukhija, Rishi, MD, Aronow, Wilbert S., MD, Palaniswamy, Chandrasekar, MD, Singh, Tarunjit, MD, Sukhija, Rashmi, MD, Kalapatapu, Kumar, MD, Mohan, Diwakar, MD, Pucillo, Anthony L., MD, Sorbera, Carmine, MD, Kakar, Priyanka, MD, Weiss, Melvin B., MD, Lal, Purshotam, MD, Monsen, Craig E., MD
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - complications
Cardiovascular Diseases - therapy
Coronary Artery Disease - etiology
Coronary Artery Disease - therapy
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Incidence
Male
Medical sciences
Middle Aged
Myocardial Infarction - etiology
Myocardial Infarction - therapy
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Paclitaxel - administration & dosage
Regression analysis
Renal failure
Renal Insufficiency - complications
Retrospective Studies
Risk factors
Sirolimus - administration & dosage
Stents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3
cites cdi_FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3
container_end_page 296
container_issue 3
container_start_page 293
container_title The American journal of cardiology
container_volume 105
creator Sukhija, Rishi, MD
Aronow, Wilbert S., MD
Palaniswamy, Chandrasekar, MD
Singh, Tarunjit, MD
Sukhija, Rashmi, MD
Kalapatapu, Kumar, MD
Mohan, Diwakar, MD
Pucillo, Anthony L., MD
Sorbera, Carmine, MD
Kakar, Priyanka, MD
Weiss, Melvin B., MD
Lal, Purshotam, MD
Monsen, Craig E., MD
description No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of
doi_str_mv 10.1016/j.amjcard.2009.09.031
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734257566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914909024023</els_id><sourcerecordid>1945875701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3</originalsourceid><addsrcrecordid>eNqFkt9qFDEUxgdR7Fp9BCUI4tWs-TObTG4sZd3WQoviLngZMslJzTg7U5PMwr6Az22mu1bojXAgCfy-Lzn5TlG8JnhOMOEf2rnetkYHO6cYy_lUjDwpZqQWsiSSsKfFDGNMS0kqeVK8iLHNR0IW_HlxQjHBVDIxK37f6HYI6NzuIERAy2zotUGrHfQpIt-jrzr5-_13n36gm8FC0AlQGtAasgbQN-h1h676ODrnTWbNHm0CZMgeNBc-xFReQj8p_dCjT2G8LVfdmHx_i9Zpcn9ZPHO6i_DquJ4Wm4vVZvm5vP5yebU8vy5NJXgqxYJRh0Vdc8OgqQUXrmlc7VyNqTbMGistz0DFKiZYTaURIFktuayZbDQ7Ld4fbO_C8GuEmNTWRwNdp3sYxqgEq-hCLDjP5NtHZDuMIXcaFWWYCSHpBC0OkAlDjAGcugt-q8NeEaymlFSrjimpKSU1FSNZ9-ZoPjZbsA-qv7Fk4N0R0NHozgXdGx__cZRJzHmVubMDB_nPdh6CivcJgPUBTFJ28P99ysdHDqbzvc-X_oQ9xIemiYpUYbWeRmqaKCwxrTBl7A8kkceV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230377926</pqid></control><display><type>article</type><title>Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Sukhija, Rishi, MD ; Aronow, Wilbert S., MD ; Palaniswamy, Chandrasekar, MD ; Singh, Tarunjit, MD ; Sukhija, Rashmi, MD ; Kalapatapu, Kumar, MD ; Mohan, Diwakar, MD ; Pucillo, Anthony L., MD ; Sorbera, Carmine, MD ; Kakar, Priyanka, MD ; Weiss, Melvin B., MD ; Lal, Purshotam, MD ; Monsen, Craig E., MD</creator><creatorcontrib>Sukhija, Rishi, MD ; Aronow, Wilbert S., MD ; Palaniswamy, Chandrasekar, MD ; Singh, Tarunjit, MD ; Sukhija, Rashmi, MD ; Kalapatapu, Kumar, MD ; Mohan, Diwakar, MD ; Pucillo, Anthony L., MD ; Sorbera, Carmine, MD ; Kakar, Priyanka, MD ; Weiss, Melvin B., MD ; Lal, Purshotam, MD ; Monsen, Craig E., MD</creatorcontrib><description>No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of &lt;60 ml/min/1.73 m2 , as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2009.09.031</identifier><identifier>PMID: 20102937</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Cardiology ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular disease ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - therapy ; Coronary Artery Disease - etiology ; Coronary Artery Disease - therapy ; Drug-Eluting Stents ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - etiology ; Myocardial Infarction - therapy ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Paclitaxel - administration &amp; dosage ; Regression analysis ; Renal failure ; Renal Insufficiency - complications ; Retrospective Studies ; Risk factors ; Sirolimus - administration &amp; dosage ; Stents</subject><ispartof>The American journal of cardiology, 2010-02, Vol.105 (3), p.293-296</ispartof><rights>2010</rights><rights>2015 INIST-CNRS</rights><rights>Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Sequoia S.A. Feb 1, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3</citedby><cites>FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22390664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20102937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sukhija, Rishi, MD</creatorcontrib><creatorcontrib>Aronow, Wilbert S., MD</creatorcontrib><creatorcontrib>Palaniswamy, Chandrasekar, MD</creatorcontrib><creatorcontrib>Singh, Tarunjit, MD</creatorcontrib><creatorcontrib>Sukhija, Rashmi, MD</creatorcontrib><creatorcontrib>Kalapatapu, Kumar, MD</creatorcontrib><creatorcontrib>Mohan, Diwakar, MD</creatorcontrib><creatorcontrib>Pucillo, Anthony L., MD</creatorcontrib><creatorcontrib>Sorbera, Carmine, MD</creatorcontrib><creatorcontrib>Kakar, Priyanka, MD</creatorcontrib><creatorcontrib>Weiss, Melvin B., MD</creatorcontrib><creatorcontrib>Lal, Purshotam, MD</creatorcontrib><creatorcontrib>Monsen, Craig E., MD</creatorcontrib><title>Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of &lt;60 ml/min/1.73 m2 , as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - therapy</subject><subject>Coronary Artery Disease - etiology</subject><subject>Coronary Artery Disease - therapy</subject><subject>Drug-Eluting Stents</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - therapy</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Paclitaxel - administration &amp; dosage</subject><subject>Regression analysis</subject><subject>Renal failure</subject><subject>Renal Insufficiency - complications</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Sirolimus - administration &amp; dosage</subject><subject>Stents</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFkt9qFDEUxgdR7Fp9BCUI4tWs-TObTG4sZd3WQoviLngZMslJzTg7U5PMwr6Az22mu1bojXAgCfy-Lzn5TlG8JnhOMOEf2rnetkYHO6cYy_lUjDwpZqQWsiSSsKfFDGNMS0kqeVK8iLHNR0IW_HlxQjHBVDIxK37f6HYI6NzuIERAy2zotUGrHfQpIt-jrzr5-_13n36gm8FC0AlQGtAasgbQN-h1h676ODrnTWbNHm0CZMgeNBc-xFReQj8p_dCjT2G8LVfdmHx_i9Zpcn9ZPHO6i_DquJ4Wm4vVZvm5vP5yebU8vy5NJXgqxYJRh0Vdc8OgqQUXrmlc7VyNqTbMGistz0DFKiZYTaURIFktuayZbDQ7Ld4fbO_C8GuEmNTWRwNdp3sYxqgEq-hCLDjP5NtHZDuMIXcaFWWYCSHpBC0OkAlDjAGcugt-q8NeEaymlFSrjimpKSU1FSNZ9-ZoPjZbsA-qv7Fk4N0R0NHozgXdGx__cZRJzHmVubMDB_nPdh6CivcJgPUBTFJ28P99ysdHDqbzvc-X_oQ9xIemiYpUYbWeRmqaKCwxrTBl7A8kkceV</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Sukhija, Rishi, MD</creator><creator>Aronow, Wilbert S., MD</creator><creator>Palaniswamy, Chandrasekar, MD</creator><creator>Singh, Tarunjit, MD</creator><creator>Sukhija, Rashmi, MD</creator><creator>Kalapatapu, Kumar, MD</creator><creator>Mohan, Diwakar, MD</creator><creator>Pucillo, Anthony L., MD</creator><creator>Sorbera, Carmine, MD</creator><creator>Kakar, Priyanka, MD</creator><creator>Weiss, Melvin B., MD</creator><creator>Lal, Purshotam, MD</creator><creator>Monsen, Craig E., MD</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20100201</creationdate><title>Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents</title><author>Sukhija, Rishi, MD ; Aronow, Wilbert S., MD ; Palaniswamy, Chandrasekar, MD ; Singh, Tarunjit, MD ; Sukhija, Rashmi, MD ; Kalapatapu, Kumar, MD ; Mohan, Diwakar, MD ; Pucillo, Anthony L., MD ; Sorbera, Carmine, MD ; Kakar, Priyanka, MD ; Weiss, Melvin B., MD ; Lal, Purshotam, MD ; Monsen, Craig E., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - therapy</topic><topic>Coronary Artery Disease - etiology</topic><topic>Coronary Artery Disease - therapy</topic><topic>Drug-Eluting Stents</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - therapy</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Paclitaxel - administration &amp; dosage</topic><topic>Regression analysis</topic><topic>Renal failure</topic><topic>Renal Insufficiency - complications</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Sirolimus - administration &amp; dosage</topic><topic>Stents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sukhija, Rishi, MD</creatorcontrib><creatorcontrib>Aronow, Wilbert S., MD</creatorcontrib><creatorcontrib>Palaniswamy, Chandrasekar, MD</creatorcontrib><creatorcontrib>Singh, Tarunjit, MD</creatorcontrib><creatorcontrib>Sukhija, Rashmi, MD</creatorcontrib><creatorcontrib>Kalapatapu, Kumar, MD</creatorcontrib><creatorcontrib>Mohan, Diwakar, MD</creatorcontrib><creatorcontrib>Pucillo, Anthony L., MD</creatorcontrib><creatorcontrib>Sorbera, Carmine, MD</creatorcontrib><creatorcontrib>Kakar, Priyanka, MD</creatorcontrib><creatorcontrib>Weiss, Melvin B., MD</creatorcontrib><creatorcontrib>Lal, Purshotam, MD</creatorcontrib><creatorcontrib>Monsen, Craig E., MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sukhija, Rishi, MD</au><au>Aronow, Wilbert S., MD</au><au>Palaniswamy, Chandrasekar, MD</au><au>Singh, Tarunjit, MD</au><au>Sukhija, Rashmi, MD</au><au>Kalapatapu, Kumar, MD</au><au>Mohan, Diwakar, MD</au><au>Pucillo, Anthony L., MD</au><au>Sorbera, Carmine, MD</au><au>Kakar, Priyanka, MD</au><au>Weiss, Melvin B., MD</au><au>Lal, Purshotam, MD</au><au>Monsen, Craig E., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>105</volume><issue>3</issue><spage>293</spage><epage>296</epage><pages>293-296</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of &lt;60 ml/min/1.73 m2 , as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20102937</pmid><doi>10.1016/j.amjcard.2009.09.031</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2010-02, Vol.105 (3), p.293-296
issn 0002-9149
1879-1913
language eng
recordid cdi_proquest_miscellaneous_734257566
source ScienceDirect Freedom Collection 2022-2024
subjects Aged
Aged, 80 and over
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - complications
Cardiovascular Diseases - therapy
Coronary Artery Disease - etiology
Coronary Artery Disease - therapy
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Incidence
Male
Medical sciences
Middle Aged
Myocardial Infarction - etiology
Myocardial Infarction - therapy
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Paclitaxel - administration & dosage
Regression analysis
Renal failure
Renal Insufficiency - complications
Retrospective Studies
Risk factors
Sirolimus - administration & dosage
Stents
title Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A32%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Major%20Adverse%20Cardiac%20Events%20in%20Patients%20With%20Moderate%20to%20Severe%20Renal%20Insufficiency%20Treated%20With%20First-Generation%20Drug-Eluting%20Stents&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Sukhija,%20Rishi,%20MD&rft.date=2010-02-01&rft.volume=105&rft.issue=3&rft.spage=293&rft.epage=296&rft.pages=293-296&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2009.09.031&rft_dat=%3Cproquest_cross%3E1945875701%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c476t-7532f07886c3eb8767fbbf8ff802ac3dcd9d6f07434373829c7e938969839ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230377926&rft_id=info:pmid/20102937&rfr_iscdi=true